Akebia Therapeutics, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · United States

Last price 0.7065 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 195.78M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia...